Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
November 10, 2023 01:35 ET
|
Sosei Group Corporation
Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage...
Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
October 31, 2023 03:30 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target...
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
October 31, 2023 03:00 ET
|
Sosei Group Corporation
NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profileSosei...
GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100
October 26, 2023 03:33 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing...
Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
October 25, 2023 04:00 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held...
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
October 10, 2023 03:00 ET
|
GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its...
Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration
October 10, 2023 03:00 ET
|
Salipro Biotech AB
Salipro Biotech and Icosagen announce the initiation of a multi-target collaboration for the discovery and characterization of monoclonal antibodies
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
October 10, 2023 02:30 ET
|
Sosei Group Corporation
The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023 07:32 ET
|
Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
September 29, 2023 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...